Trial · NCT04348513
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
NCT04348513, Phase 2, Terminated, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. Trials, record NCT04348513. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04348513
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
- NCT number
- NCT04348513
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
- Conditions
- Pulmonary Infection, Covid-19
- Interventions
- T3 solution for injection, Placebo
- First posted
- 2020-04-16
- Last updated
- 2021-09-23
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of weaning from cardiorespiratory support | 30 days | The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo. Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours. The primary objective will be measured as percentage of patients successfully weaned after 30 days of follow-up. |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (systolic BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (diastolic BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by continuous blood pressure measurements (mean BP in mmHg) |
| Secondary | Assessment of hemodynamic status | 30 days | Hemodynamic status will be assessed by the number of participants with use of inotropic and vasoactive drugs |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of oxygen in mmHg) |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of blood gases (arterial partial pressure of carbon dioxide in mmHg) |
| Secondary | Assessment of pulmonary function | 30 days | Pulmonary function will be assessed by arterial measurement of lactate levels (in mmol/L) |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in aspartate aminotransferase (AST in IU/L) will be measured. |
| Secondary | Assessment of hepatic function | 30 days | Hepatic function will be assessed by laboratory measurements in blood. Changes in alanine aminotransferase (ALT in IU/L) will be measured. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04348513
GET https://conductscience.org/api/trials/v1/NCT04348513/registered?page=2